Blood-based nucleic acid biomarkers as a potential tool to determine radiation therapy response in non-small cell lung cancer

Christopher R. Deig, Marc Mendonca, Tim Lautenschlaeger

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Lung cancer is the leading cause of cancer deaths worldwide, with smoking as the main risk factor. The use of low-dose computed tomography (LDCT) as a screening method has shown a 20% lung cancer specific mortality benefit; however, widespread implementation is estimated to add1.3-$2.0 billion in annual national health care expenditures. Blood-based microRNAs (miRNAs) have been investigated in detail and found to be potentially useful biomarkers indicating the presence of lung cancer, especially when used as a companion test to LDCT. Testing for miRNAs and circulating tumor DNA (ct-DNA) in the blood are anticipated to become more affordable in the near future, and therefore these potentially sensitive methods could serve as first-line screening modalities prior to obtaining LDCT and definitive diagnostic tests for lung cancer. Furthermore, miRNAs may shed light not only on the tumor burden, but also perhaps on tumor aggressiveness, histology, treatment response and the patient's overall survival. In the near future, analysis of ct-DNA may reveal somatic mutations beyond EGFR, tumor burden and the presence of occult progression of disease. In theory, these biomarkers may also help oncologists to elucidate the tumor response to radiotherapy, and in the future, may assist the radiation oncologist in making data-driven treatment decisions and providing patients with quantitative information regarding their treatment response.

Original languageEnglish (US)
Pages (from-to)333-338
Number of pages6
JournalRadiation Research
Volume187
Issue number3
DOIs
StatePublished - Mar 1 2017

Fingerprint

biomarkers
nucleic acids
Non-Small Cell Lung Carcinoma
lungs
Nucleic Acids
blood
radiation therapy
Radiotherapy
tumors
Biomarkers
cancer
Lung Neoplasms
MicroRNAs
Tomography
Neoplasms
Tumor Burden
tomography
dosage
screening
deoxyribonucleic acid

ASJC Scopus subject areas

  • Radiation
  • Biophysics
  • Radiology Nuclear Medicine and imaging

Cite this

Blood-based nucleic acid biomarkers as a potential tool to determine radiation therapy response in non-small cell lung cancer. / Deig, Christopher R.; Mendonca, Marc; Lautenschlaeger, Tim.

In: Radiation Research, Vol. 187, No. 3, 01.03.2017, p. 333-338.

Research output: Contribution to journalArticle

@article{75045c1b28c744889376ba136531d66d,
title = "Blood-based nucleic acid biomarkers as a potential tool to determine radiation therapy response in non-small cell lung cancer",
abstract = "Lung cancer is the leading cause of cancer deaths worldwide, with smoking as the main risk factor. The use of low-dose computed tomography (LDCT) as a screening method has shown a 20{\%} lung cancer specific mortality benefit; however, widespread implementation is estimated to add1.3-$2.0 billion in annual national health care expenditures. Blood-based microRNAs (miRNAs) have been investigated in detail and found to be potentially useful biomarkers indicating the presence of lung cancer, especially when used as a companion test to LDCT. Testing for miRNAs and circulating tumor DNA (ct-DNA) in the blood are anticipated to become more affordable in the near future, and therefore these potentially sensitive methods could serve as first-line screening modalities prior to obtaining LDCT and definitive diagnostic tests for lung cancer. Furthermore, miRNAs may shed light not only on the tumor burden, but also perhaps on tumor aggressiveness, histology, treatment response and the patient's overall survival. In the near future, analysis of ct-DNA may reveal somatic mutations beyond EGFR, tumor burden and the presence of occult progression of disease. In theory, these biomarkers may also help oncologists to elucidate the tumor response to radiotherapy, and in the future, may assist the radiation oncologist in making data-driven treatment decisions and providing patients with quantitative information regarding their treatment response.",
author = "Deig, {Christopher R.} and Marc Mendonca and Tim Lautenschlaeger",
year = "2017",
month = "3",
day = "1",
doi = "10.1667/RR14613.1",
language = "English (US)",
volume = "187",
pages = "333--338",
journal = "Radiation Research",
issn = "0033-7587",
publisher = "Radiation Research Society",
number = "3",

}

TY - JOUR

T1 - Blood-based nucleic acid biomarkers as a potential tool to determine radiation therapy response in non-small cell lung cancer

AU - Deig, Christopher R.

AU - Mendonca, Marc

AU - Lautenschlaeger, Tim

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Lung cancer is the leading cause of cancer deaths worldwide, with smoking as the main risk factor. The use of low-dose computed tomography (LDCT) as a screening method has shown a 20% lung cancer specific mortality benefit; however, widespread implementation is estimated to add1.3-$2.0 billion in annual national health care expenditures. Blood-based microRNAs (miRNAs) have been investigated in detail and found to be potentially useful biomarkers indicating the presence of lung cancer, especially when used as a companion test to LDCT. Testing for miRNAs and circulating tumor DNA (ct-DNA) in the blood are anticipated to become more affordable in the near future, and therefore these potentially sensitive methods could serve as first-line screening modalities prior to obtaining LDCT and definitive diagnostic tests for lung cancer. Furthermore, miRNAs may shed light not only on the tumor burden, but also perhaps on tumor aggressiveness, histology, treatment response and the patient's overall survival. In the near future, analysis of ct-DNA may reveal somatic mutations beyond EGFR, tumor burden and the presence of occult progression of disease. In theory, these biomarkers may also help oncologists to elucidate the tumor response to radiotherapy, and in the future, may assist the radiation oncologist in making data-driven treatment decisions and providing patients with quantitative information regarding their treatment response.

AB - Lung cancer is the leading cause of cancer deaths worldwide, with smoking as the main risk factor. The use of low-dose computed tomography (LDCT) as a screening method has shown a 20% lung cancer specific mortality benefit; however, widespread implementation is estimated to add1.3-$2.0 billion in annual national health care expenditures. Blood-based microRNAs (miRNAs) have been investigated in detail and found to be potentially useful biomarkers indicating the presence of lung cancer, especially when used as a companion test to LDCT. Testing for miRNAs and circulating tumor DNA (ct-DNA) in the blood are anticipated to become more affordable in the near future, and therefore these potentially sensitive methods could serve as first-line screening modalities prior to obtaining LDCT and definitive diagnostic tests for lung cancer. Furthermore, miRNAs may shed light not only on the tumor burden, but also perhaps on tumor aggressiveness, histology, treatment response and the patient's overall survival. In the near future, analysis of ct-DNA may reveal somatic mutations beyond EGFR, tumor burden and the presence of occult progression of disease. In theory, these biomarkers may also help oncologists to elucidate the tumor response to radiotherapy, and in the future, may assist the radiation oncologist in making data-driven treatment decisions and providing patients with quantitative information regarding their treatment response.

UR - http://www.scopus.com/inward/record.url?scp=85016391626&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016391626&partnerID=8YFLogxK

U2 - 10.1667/RR14613.1

DO - 10.1667/RR14613.1

M3 - Article

C2 - 28186469

AN - SCOPUS:85016391626

VL - 187

SP - 333

EP - 338

JO - Radiation Research

JF - Radiation Research

SN - 0033-7587

IS - 3

ER -